Drug and Therapeutics Bulletin 1997;35:62-64; doi:10.1136/dtb.1997.35862
Copyright © 1997 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Progenitor cell transplantation

Relevant BNF section: 9.1.6

Many leukaemias and solid cancers are now treated with high-dose chemotherapy, an approach made possible by techniques that bolster haematological recovery when bone marrow suppression occurs. The conventional way of reversing marrow suppression has been to give an autologous bone marrow transplant (cells aspirated from the patient's own marrow). A newer technique, progenitor cell transplantation, also known as stem cell transplantation, is replacing bone marrow transplantation in this setting. It uses progenitor cells (derived from the pluripotent stem cells) which give rise to mature blood cells. These cells are taken from the patient's peripheral circulation and re-infused after high-dose chemotherapy. Here we describe progenitor cell transplantation and discuss how it compares with bone marrow transplantation.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1997 BMJ Publishing Group Ltd.